HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early administration of fluvastatin, but not at the onset of ischemia or reperfusion, attenuates myocardial ischemia-reperfusion injury through the nitric oxide pathway rather than its antioxidant property.

AbstractBACKGROUND:
Three-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are known to attenuate myocardial ischemia-reperfusion (IR) injury. Fluvastatin (FV) has a potent free radical scavenging action, but it is unclear whether the timing of FV administration could affect its cardioprotective effect or if the antioxidant property of FV might attenuate IR injury.
METHODS AND RESULTS:
IR was induced in rats by left coronary artery occlusion for 30 min followed by 24-h reperfusion. The rats were divided into 4 groups: oral FV group (10 mg/kg per day for 2 weeks before ischemia); iv, FV group (10 mg/kg) before ischemia; iv, FV group (10 mg/kg) before reperfusion; and control group. Oxidative stress was evaluated by myocardial 8-hydroxydeoxyguanosine (8-OHdG) content. The area at risk did not different among the 4 groups. Pretreatment with FV for 2 weeks significantly reduced the infarct size by 28% as compared with the control group, but FV administered just before ischemia or reperfusion did not. Myocardial 8-OHdG content was not affected by FV. The infarct-sparing effect of FV was completely abolished by N(omega)-nitro-l-arginine methyl ester or wortmannin.
CONCLUSIONS:
The present results indicate that pretreatment with FV, but not just before ischemia or reperfusion, attenuates IR injury primarily through the nitric oxide pathway, not through its antioxidant property.
AuthorsAkira Matsuki, Akihiko Igawa, Takashi Nozawa, Teruo Nakadate, Norio Igarashi, Makoto Nonomura, Hiroshi Inoue
JournalCirculation journal : official journal of the Japanese Circulation Society (Circ J) Vol. 70 Issue 12 Pg. 1643-9 (Dec 2006) ISSN: 1346-9843 [Print] Japan
PMID17127814 (Publication Type: Journal Article)
Chemical References
  • Antioxidants
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Lipids
  • Nitric Oxide
  • Fluvastatin
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine
Topics
  • 8-Hydroxy-2'-Deoxyguanosine
  • Animals
  • Antioxidants (administration & dosage, pharmacology)
  • Deoxyguanosine (analogs & derivatives, metabolism)
  • Fatty Acids, Monounsaturated (administration & dosage, pharmacology)
  • Fluvastatin
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage, pharmacology)
  • Indoles (administration & dosage, pharmacology)
  • Lipids (blood)
  • Male
  • Myocardial Infarction (pathology)
  • Myocardial Reperfusion Injury (prevention & control)
  • Myocardium (metabolism)
  • Nitric Oxide (metabolism)
  • Oxidative Stress (drug effects)
  • Rats
  • Rats, Wistar

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: